openPR Logo
Press release

Relapsed or Refractory Myelodysplastic Syndrome Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024

02-29-2024 05:55 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Relapsed or Refractory Myelodysplastic Syndrome Pipeline

Relapsed or Refractory Myelodysplastic Syndrome Pipeline

DelveInsight's, "Relapsed or Refractory Myelodysplastic Syndrome Pipeline Insight 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape. It covers the Relapsed or Refractory Myelodysplastic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Relapsed or Refractory Myelodysplastic Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Relapsed or Refractory Myelodysplastic Syndrome Pipeline Report
• DelveInsight's Relapsed or Refractory Myelodysplastic Syndrome pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Relapsed or Refractory Myelodysplastic Syndrome treatment.
• The leading companies working in the Relapsed or Refractory Myelodysplastic Syndrome Market include Cantex Pharmaceuticals, Novartis, Newave Pharmaceuticals, BioTheryX, Agios Pharmaceuticals, and others.
• Promising Relapsed or Refractory Myelodysplastic Syndrome Pipeline Therapies in the various stages of development include CX-01, Azacitidine, SyB C-1101, NC525, LP-108, CC-91633, Talacotuzumab, Daratumumab, CC-90009, BTX-A51, and others.
• November 2023: NextCure Inc. announced a study of Phase 1 clinical trials for NC525. This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms. A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms.
• October 2023: Celgene announced a study of Phase 1 clinical trials for CC-91633. A Phase 1, Open-label, Dose-finding Study of CC-91633 (BMS-986397) in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes.Study CC-91633-AML-001 is a Phase 1, open-label, dose escalation and expansion, first-in-human (FIH) clinical study of CC-91633 (BMS-986397) in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). The Dose Escalation part (Part A) of the study will enroll participants with R/R AML and R/R HR-MDS and will evaluate the safety and tolerability of escalating doses of CC-91633 (BMS-986397), administered orally, and determine the maximum tolerated dose (MTD) or preliminary recommended Phase 2 dose (RP2D) and schedule.
• October 2023: Thomas Jefferson University announced a study of Phase 1 & 2 clinical trials for Venetoclax and Decitabine. This phase Ib/II trial tests the safety, side effects, and best dose of navitoclax in combination with venetoclax and decitabine in treating patients with higher risk myelodysplastic syndrome (MDS) that has come back after initial treatment or was not responsive to initial treatment. This study will also look at the effectiveness of the treatment combination and patient's quality of life while on these medications. Navitoclax is an oral drug that works as an inhibitor of the BCL-2 family of proteins, which are often overly expressed in a wide variety of cancers and are linked to tumor drug resistance. This drug blocks some of the enzymes that keep cancer cells from dying. Venetoclax is an oral drug that works as an inhibitor of BCL-2 proteins that works very similarly to navitoclax by blocking the action of a certain proteins in the body that helps cancer cells survive which helps to kill cancer cells.
• October 2023: M.D. Anderson Cancer Center announced a study of Phase 1 & 2 clinical trials for Akt/ERK Inhibitor ONC201. This phase I/II trial studies the side effects and best dose of ONC201 and to see how well it works in treating patients with acute leukemia or high-risk myelodysplastic syndrome that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). ONC201 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Request a sample and discover the recent advances in Relapsed or Refractory Myelodysplastic Syndrome Treatment Drugs @ Relapsed or Refractory Myelodysplastic Syndrome Pipeline Report- https://www.delveinsight.com/report-store/relapsed-or-refractory-myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Relapsed or Refractory Myelodysplastic Syndrome pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsed or Refractory Myelodysplastic Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Relapsed or Refractory Myelodysplastic Syndrome Overview
Myelodysplastic syndromes (MDS) are defined by ineffective hematopoiesis resulting in blood cytopenias, and clonal instability with a risk of clonal evolution to acute myeloid leukemia (AML).Patients with MDS collectively have a high symptom burden and are also at risk of death from complications of cytopenias and AML3.

Find out more about Relapsed or Refractory Myelodysplastic Syndrome Therapeutics Assessment @ Relapsed or Refractory Myelodysplastic Syndrome Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/relapsed-or-refractory-myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Relapsed or Refractory Myelodysplastic Syndrome Emerging Drugs Profile
• CX-01: Cantex Pharmaceuticals
• LP-108: Newave Pharmaceuticals
• BTX-A51: BioTheryX

Relapsed or Refractory Myelodysplastic Syndrome Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the Relapsed or Refractory Myelodysplastic Syndrome therapies. The Relapsed or Refractory Myelodysplastic Syndrome companies which have their Relapsed or Refractory Myelodysplastic Syndrome drug candidates in the mid to advanced stage, i.e. Phase II include, Cantex Pharmaceuticals and others.

DelveInsight's Relapsed or Refractory Myelodysplastic Syndrome Pipeline report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Relapsed or Refractory Myelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Parenteral
• Molecule Type

Relapsed or Refractory Myelodysplastic Syndrome Pipeline Products have been categorized under various Molecule types such as
• Small molecules
• Polymer
• Peptide
• Gene Therapy
• Monoclonal antibodies
• Product Type

Learn more about the emerging Relapsed or Refractory Myelodysplastic Syndrome Pipeline Therapies @ Relapsed or Refractory Myelodysplastic Syndrome Clinical Trials Assessment- https://www.delveinsight.com/sample-request/relapsed-or-refractory-myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Relapsed or Refractory Myelodysplastic Syndrome Pipeline Report
• Coverage- Global
• Relapsed or Refractory Myelodysplastic Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Relapsed or Refractory Myelodysplastic Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Relapsed or Refractory Myelodysplastic Syndrome Companies- Cantex Pharmaceuticals, Novartis, Newave Pharmaceuticals, BioTheryX, Agios Pharmaceuticals, and others.
• Relapsed or Refractory Myelodysplastic Syndrome Pipeline Therapies- CX-01, Azacitidine, SyB C-1101, NC525, LP-108, CC-91633, Talacotuzumab, Daratumumab, CC-90009, BTX-A51, and others.

Dive deep into rich insights for new drugs for Relapsed or Refractory Myelodysplastic Syndrome Treatment, Visit @ Relapsed or Refractory Myelodysplastic Syndrome Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/relapsed-or-refractory-myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Relapsed or Refractory Myelodysplastic Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Relapsed or Refractory Myelodysplastic Syndrome - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Relapsed or Refractory Myelodysplastic Syndrome Collaboration Deals
9. Late Stage Products (Phase III)
10. AG-120: Agios Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. CX-01: Cantex Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early-Stage Products (Phase I)
16. BTX A51: BioTheryX
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Relapsed or Refractory Myelodysplastic Syndrome Key Companies
20. Relapsed or Refractory Myelodysplastic Syndrome Key Products
21. Relapsed or Refractory Myelodysplastic Syndrome- Unmet Needs
22. Relapsed or Refractory Myelodysplastic Syndrome- Market Drivers and Barriers
23. Relapsed or Refractory Myelodysplastic Syndrome- Future Perspectives and Conclusion
24. Relapsed or Refractory Myelodysplastic Syndrome Analyst Views
25. Relapsed or Refractory Myelodysplastic Syndrome Key Companies
26. Appendix

For further information on the Relapsed or Refractory Myelodysplastic Syndrome Pipeline therapeutics, reach out to Relapsed or Refractory Myelodysplastic Syndrome Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/relapsed-or-refractory-myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market
https://www.delveinsight.com/report-store/glaucoma-market
https://www.delveinsight.com/report-store/uveitis-market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
https://www.delveinsight.com/report-store/nephrotic-syndrome-market
https://www.delveinsight.com/report-store/short-bowel-syndrome-market
https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market
https://www.delveinsight.com/report-store/retinitis-pigmentosa-market
https://www.delveinsight.com/report-store/aplastic-anemia-market
https://www.delveinsight.com/report-store/cystic-fibrosis-market
https://www.delveinsight.com/report-store/heart-failure-market
https://www.delveinsight.com/report-store/peanut-allergy-market
https://www.delveinsight.com/report-store/smoking-cessation-market
https://www.delveinsight.com/report-store/post-operative-pain-management-market
https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-market
https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Relapsed or Refractory Myelodysplastic Syndrome Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 here

News-ID: 3406059 • Views:

More Releases from DelveInsight Business Research LLP

Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical Stage Assets, Pharma Collaborations, Regulatory Developments, and the Global Market Growth Prospects
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Current Drug Trials, Potential Breakthrough Therapies, Pharma R&D Initiatives, and Future Market Transformations
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinical Advances, Pharma Strategies, and Market Evolution
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action, Ongoing Clinical Trials, Pharma Collaborations, and the Future Outlook of the Therapeutics Landscape
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights!

All 5 Releases


More Releases for Relapsed

Relapsed Chronic Lymphocytic Leukemia Market to Reach USD 19.5 Billion by 2034
Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western countries, characterized by the accumulation of dysfunctional B lymphocytes. While initial therapies often induce remission, many patients experience relapse, progressing to relapsed or refractory CLL, which presents significant clinical challenges. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71569 Over the past decade, the treatment paradigm has shifted from chemotherapy to targeted therapies and immunotherapies, including BTK
Relapsed/Refractory Acute Myeloid Pipeline Therapeutics Assessment Report 2024 ( …
DelveInsight's, "Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the Relapsed/Refractory Acute Myeloid Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Relapsed/Refractory Acute Myeloid Leukemia Clinical Trials, Treatment Drugs, Pip …
DelveInsight's, "Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the Relapsed/Refractory Acute Myeloid Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Relapsed/Refractory Acute Myeloid Leukemia Pipeline 2024
DelveInsight's, "Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the Relapsed/Refractory Acute Myeloid Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Outlook Report 2024
DelveInsight's, "Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight, 2024" report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Relapsed/Refractory
Relapsed Refractory Multiple Myeloma Market Report 2024-2034 | Industry Size, Gr …
Market Overview: The relapsed refractory multiple myeloma market reached a value of US$ 21.0 Billion in 2023 and expected to reach US$ 34.4 Billion by 2034, exhibiting a growth rate (CAGR) of 4.61% during 2024-2034. The report offers a comprehensive analysis of the relapsed refractory multiple myeloma market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs